AngioDynamics, Inc. (ANGO), a medical device company based in Latham, New York, is gearing up to announce its first-quarter earnings results before the market opens on Thursday, October 3.
Analysts are expecting the company to report a quarterly loss of 15 cents per share, a slight increase from the 12 cents per share loss recorded in the same period last year. Revenue for the quarter is projected to reach $67.93 million.
In recent news, AngioDynamics received CE Mark approval for its Auryon System in Europe on September 3. This approval could significantly boost the company’s international presence and sales.
Looking at recent analyst ratings, the sentiment towards AngioDynamics appears positive.
HC Wainwright analyst Yi Chen reiterated a Buy rating with a price target of $14 on September 20. Chen, who boasts an accuracy rate of 63%, believes AngioDynamics has the potential to deliver strong growth in the future.
Oppenheimer analyst Steven Lichtman upgraded the stock from Perform to Outperform with a price target of $12 on April 5. Lichtman, known for his 74% accuracy rate, sees AngioDynamics as a compelling investment opportunity.
Raymond James analyst Jayson Bedford, who has a 71% accuracy rate, maintained an Outperform rating on AngioDynamics but reduced the price target from $12 to $10 on January 9.
Overall, the analysts’ ratings and price targets suggest a positive outlook for AngioDynamics, indicating potential for growth and value appreciation. Investors considering buying ANGO stock should carefully evaluate the company’s financial performance and future prospects before making any investment decisions.
